Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Common Equity (2017 - 2025)

Historic Common Equity for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $13.2 million.

  • Cue Biopharma's Common Equity fell 4778.05% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year decrease of 4778.05%. This contributed to the annual value of $17.5 million for FY2024, which is 5281.38% down from last year.
  • Cue Biopharma's Common Equity amounted to $13.2 million in Q3 2025, which was down 4778.05% from $18.2 million recorded in Q2 2025.
  • Cue Biopharma's 5-year Common Equity high stood at $72.9 million for Q2 2021, and its period low was $6.6 million during Q1 2025.
  • Moreover, its 5-year median value for Common Equity was $46.0 million (2023), whereas its average is $43.5 million.
  • In the last 5 years, Cue Biopharma's Common Equity surged by 5401.23% in 2021 and then crashed by 7809.44% in 2025.
  • Cue Biopharma's Common Equity (Quarter) stood at $65.5 million in 2021, then increased by 0.29% to $65.7 million in 2022, then crashed by 43.54% to $37.1 million in 2023, then crashed by 52.81% to $17.5 million in 2024, then fell by 24.3% to $13.2 million in 2025.
  • Its Common Equity was $13.2 million in Q3 2025, compared to $18.2 million in Q2 2025 and $6.6 million in Q1 2025.